1. Home
  2. IRMD vs DBVT Comparison

IRMD vs DBVT Comparison

Compare IRMD & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRadimed Corporation

IRMD

iRadimed Corporation

N/A

Current Price

$101.41

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

DBVT

DBV Technologies S.A.

N/A

Current Price

$21.32

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IRMD
DBVT
Founded
1992
2002
Country
United States
France
Employees
N/A
90
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
IRMD
DBVT
Price
$101.41
$21.32
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$31.75
AVG Volume (30 Days)
51.0K
292.0K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
0.79%
N/A
EPS Growth
11.11
N/A
EPS
1.25
N/A
Revenue
$73,242,121.00
$4,151,000.00
Revenue This Year
$11.99
$1,768.71
Revenue Next Year
$9.91
$1,028.88
P/E Ratio
$80.71
N/A
Revenue Growth
11.71
N/A
52 Week Low
$47.48
$3.82
52 Week High
$107.90
$26.19

Technical Indicators

Market Signals
Indicator
IRMD
DBVT
Relative Strength Index (RSI) 50.82 51.48
Support Level $92.51 $20.25
Resistance Level $106.42 $25.52
Average True Range (ATR) 3.59 1.35
MACD 0.09 -0.25
Stochastic Oscillator 46.05 31.00

Price Performance

Historical Comparison
IRMD
DBVT

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: